Sabby Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Sabby Management’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3	Closed	-$11K	–	149
2022 Q2	$11K	Buy	+3	New	+$94	0.01%	122
2021 Q4	–	Sell	-43	Closed	-$293K	–	220
2021 Q3	$293K	Buy	+43	New	+$3.15K	0.04%	133
2021 Q2	–	Sell	-43	Closed	-$285K	–	194
2021 Q1	$285K	Buy	43 +21	+95%	+$1.64K	0.06%	123
2020 Q4	$76K	Hold	22	–	–	0.01%	97
2020 Q3	$122K	Buy	+22	New	+$1.3K	0.02%	113
2020 Q1	–	Sell	-2	Closed	-$8K	–	113
2019 Q4	$8K	Hold	2	–	–	﹤0.01%	71
2019 Q3	$8K	Buy	+2	New	+$144	﹤0.01%	91
2017 Q4	–	Sell	-8	Closed	-$300K	–	194
2017 Q3	$300K	Sell	8 -10	-56%	-$3.55K	0.02%	119
2017 Q2	$651K	Buy	+18	New	+$5.39K	0.04%	123
2017 Q1	–	Sell	-2	Closed	-$42K	–	332
2016 Q4	$42K	Hold	2	–	–	﹤0.01%	286
2016 Q3	$51K	Buy	+2	New	+$416	﹤0.01%	300

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sabby Management's DMK Position: Q2 2020 in Review

Sabby Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2020, closing a stake of 1,260 shares — an estimated $32K sold.

Sabby Management first reported a position in DMK in Q4 2013 and held it in 5 quarters. The position peaked at $2.6M in Q4 2013. 47 funds tracked by Wall St. Rank hold DMK as of Q2 2020.

Sabby Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2020 after selling out during the quarter.
Sabby Management sold 1,260 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2020, an estimated $32K.
Sabby Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2013 and held it in 5 quarters.
Sabby Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $2.6M in Q4 2013.
47 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2020.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.